Published by Josh White on 21st March 2024
(Sharecast News) - Avacta Group announced a significant milestone in its phase 1a dose escalation study of AVA6000, its lead 'preCISION' drug, on Thursday.
URL: http://www.digitallook.com/dl/news/story/34172181/...